linaclotide · Linzess
Peptide
Evidence outlook
Approved: Irritable Bowel Syndrome with Constipation
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- Chronic idiopathic constipation (CIC) in adults
- Functional constipation (FC) in pediatric patients 2 years of age and older
- Adult patients with IBS-C (Linzess, AstraZeneca partner)
- Irritable bowel syndrome with constipation (IBS-C); chronic constipation added August 2018 (Linzess, Astellas)
- Symptomatic treatment of moderate to severe IBS-C in adults (marketed in the EU as Constella)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00730171 NCT00730171 · Irritable Bowel Syndrome With Constipation, Chronic Constipation The study was an open-label rollover/extension of participants from earlier trials MCP-103-302, MCP-103-303, MCP-103-004, MCP-103-005, MCP-103-201, or MCP-103-202, with 1,725 participants receiving linaclotide and no randomized or blinded comparator arm. Its primary endpoint was treatment-emergent adverse events, so it provides useful long-term safety information but does not establish comparative efficacy. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT00730171 | 3 | Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) (From first dose of open-label study drug up to 78 weeks) 2012-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 4 more trials
NCT00948818 NCT00948818 · Irritable Bowel Syndrome with Constipation Linaclotide was compared with a matching placebo in 803 randomly assigned adults, with participants, carers, investigators and assessors all blinded. All four primary symptom responder endpoints were met (main combined pain and bowel movement endpoint: 49 of 405 versus 20 of 395, p=0.0004), and the registry reports an expected power of 93% for the primary analysis. Registry: NCT00948818 | 3 | Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Abdominal Pain Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks. (Change from Baseline to Week 12) 2010-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03573908 NCT03573908 · Irritable Bowel Syndrome with Constipation 614 adults were randomly assigned to linaclotide or a matching placebo, with participants and investigators blinded. The primary endpoint, change in a daily abdominal symptom score covering bloating, discomfort and pain, was met (difference -0.72 points, p<0.0001). The protocol's sample-size calculation called for 600 randomized patients, and 614 were randomized. Registry: NCT03573908 | 3 | Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)) 2019-03-13 | Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)): Placebo -1.182 score on a scale (Standard Error 0.109) | Linaclotide 290 µg -1.898 score on a scale (Standard Error 0.111) | Reliable signal | link ↗ |
NCT04026113 NCT04026113 · Irritable Bowel Syndrome with Constipation The trial is shown here for IBS-C, and its IBS-C cohort randomly assigned 108 children to linaclotide 145 or 290 micrograms with no placebo group. The 12-week abdominal pain and bowel movement responder rates were 22.6% and 23.4%, and the registry posts no statistical comparison for this cohort, so it gives descriptive data only. The trial's placebo-controlled cohort of 330 children studied functional constipation, a different condition. Registry: NCT04026113 | 3 | Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period (Baseline, up to 12 weeks); Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks APS (Abdominal Pain and SBM) + 2 Responder Rate 2024-05-20 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT00938717 NCT00938717 · Irritable Bowel Syndrome with Constipation Registry: NCT00938717 | 3 | Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Abdominal Pain Responder, 9 Out of 12 Weeks (Change from Baseline to Week 12); Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks (Change from Baseline to Week 12) 2010-09 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Irritable Bowel Syndrome with Constipation: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Linaclotide (Linzess): this drug | Approved | Peptide | Guanylate cyclase-C (GC-C) | Weak signal | NCT03573908: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)): Placebo -1.182 score on a scale (Standard Error 0.109) | Linaclotide 290 µg -1.898 score on a scale (Standard Error 0.111) | |
| Tenapanor (Ibsrela) | Approved | Small molecule | NHE3 (sodium/hydrogen exchanger isoform 3) | Reliable signal | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 3(overall) | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Linzess (linaclotide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.